When someone receives a cancer diagnosis, the number of tests that follow can feel overwhelming, and the language around them does not always help. Tumor profiling and genetic testing are two terms that get used in the same conversations, sometimes as though they mean the same thing. They do not. They look at different material, answer different questions, and feed into different parts of the clinical decision-making process. Knowing what each one is actually doing makes the experience of going through both considerably less confusing.
The simplest way to hold the distinction is this: germline genetic testing is about the person. Tumor profiling is about cancer. They are related but they are not the same investigation, and the result of one does not substitute for the result of the other.
What Germline Genetic Testing Is Looking For
Germline testing uses DNA from normal body cells, typically obtained via a blood or saliva sample, to identify inherited genetic variants present from birth across every cell in the body. The goal is to determine whether an individual carries a hereditary predisposition to cancer.
- Examples: Inherited mutations in BRCA1 or BRCA2 (associated with hereditary breast and ovarian cancer) or mutations in mismatch repair (MMR) genes linked to Lynch syndrome (associated with colorectal and endometrial cancers).
- Family Implications: Unlike somatic tumor testing, germline findings directly impact blood relatives. Identifying a pathogenic germline variant allows parents, siblings, and children to pursue cascade testing and proactive risk-reduction or surveillance protocols.
What Tumor Profiling Is Looking For
Tumor profiling takes a different sample and asks a different question entirely. The DNA analyzed here comes from the cancer cells, not from the normal cells of the body. Cancer cells accumulate mutations during their development that the rest of the body does not carry. These somatic mutations, as they are called, are specific to that tumor. Two people with the same cancer diagnosis, even the same cancer type at the same stage, can have quite different mutation profiles in their tumors, and those differences affect which treatments are most likely to work.
The tumor profiling test through MedGenome’s TumourTrack Advance platform maps these somatic mutations to identify variants with known associations to treatment response or resistance, which gives the oncologist a molecular picture of the cancer rather than relying solely on its tissue of origin and stage.
This is where a distinction that trips people up regularly becomes important. A tumor profiling result that finds a BRCA mutation in the cancer cells does not mean the person has a hereditary BRCA variant. Somatic BRCA mutations occur in cancer cells as part of the mutation accumulation process and are not inherited. Germline testing is the only way to determine whether a BRCA variant is hereditary, and one test cannot substitute for the other in answering that question.
When Both Are Needed
A patient going through cancer treatment may end up having both types of testing, at different points and for different reasons, and that is not redundant. The germline result informs decisions about family members, future cancer surveillance, and in some cases whether specific drug classes that target hereditary variants are relevant. The tumor profiling result informs which targeted therapies or immunotherapy approaches are most likely to work against the specific molecular characteristics of the cancer being treated. Neither result makes the other unnecessary.
The tumor DNA testing that comprehensive tumor profiling provides can also track how a cancer changes under treatment. Cancers are not static. They evolve, and the mutations present at diagnosis may shift over time as the cells that are less affected by treatment survive and multiply. Serial profiling at different treatment points gives a picture of that evolution, which matters when a treatment that was working begins to lose effectiveness, and the clinical team needs to understand why.
Liquid Biopsy as an Alternative to Tissue Sampling
While traditional tumor profiling requires a tissue biopsy, obtaining an adequate tissue sample is not always feasible, especially for deep-seated tumors, high-risk patients, or during ongoing treatment monitoring.
Liquid Biopsy evaluates circulating tumor DNA (ctDNA) shed by tumor cells into the bloodstream, accessible via a standard blood draw.
- Primary Advantages: Non-invasive, easily repeatable, and minimizes spatial sampling bias by capturing ctDNA from multiple metastatic sites.
- Clinical Utility: Highly effective for serial monitoring, tracking treatment response, and detecting minimal residual disease (MRD) or emerging resistance mutations over time.
- Sensitivity Considerations: Tissue biopsies remain the gold standard for initial comprehensive tumor profiling due to higher DNA yields. However, blood-based liquid biopsies such as MedGenome’s OncoTrack provide an essential, non-invasive alternative when tissue is insufficient, or repeat sampling is necessary.
